LENZ Therapeutics's top three insider shareholders as of September 29, 2026 are Venture Capital Vi, L.P. Versant (TenPercentOwner, 1.81Mn shares), Biocapital, L.P. Samsara (TenPercentOwner, 1.21Mn shares), Biocapital, L.P. Samsara (TenPercentOwner, 1.15Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 1,050,599 | 764,127 | 1,814,726 | 47.0% | 02 Oct, 2025 |
| 2 | Biocapital, L.P. Samsara | TenPercentOwner | 0 | 1,208,498 | 1,208,498 | 31.3% | 13 Apr, 2022 |
| 3 | Capital Management, L.P. Ra | Director, TenPercentOwner | 0 | 672,706 | 672,706 | 17.4% | 25 Mar, 2024 |
| 4 | Evert B. Schimmelpennink | President, Ceo And Secretary | 77,289 | 0 | 77,289 | 2.0% | 30 Mar, 2026 |
| 5 | Phil Gutry | Chief Business Officer | 42,850 | 0 | 42,850 | 1.1% | 13 Apr, 2022 |
| 6 | Marc Odrich | Chief Medical Officer | 14,229 | 0 | 14,229 | 0.4% | 25 Mar, 2024 |
| 7 | Daniel R. Chevallard | Chief Financial Officer | 12,886 | 0 | 12,886 | 0.3% | 30 Mar, 2026 |
| 8 | James W Mccollum | Director | 10,500 | 0 | 10,500 | 0.3% | 10 Nov, 2025 |
| 9 | Jeffrey P. George | Director | 5,592 | 0 | 5,592 | 0.1% | 30 Mar, 2026 |
| 10 | Shawn Olsson | Chief Commercial Officer | 4,733 | 0 | 4,733 | 0.1% | 19 Nov, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 15 Jun, 2026 | Capital Management, L.P. Ra | Director, TenPercentOwner | Acquired A | 22,100 | $0.00 | $0 | 22,100 | Indirect |
| 15 Jun, 2026 | Kimberlee C Drapkin | Director | Acquired A | 22,100 | $0.00 | $0 | 22,100 | Direct |
| 15 Jun, 2026 | Zachary Scheiner | Director | Acquired A | 22,100 | $0.00 | $0 | 22,100 | Direct |
| 15 Jun, 2026 | James W Mccollum | Director | Acquired A | 22,100 | $0.00 | $0 | 22,100 | Direct |
| 15 Jun, 2026 | Frederic Guerard | Director | Acquired A | 22,100 | $0.00 | $0 | 22,100 | Direct |
| 15 Jun, 2026 | Jeffrey P. George | Director | Acquired A | 22,100 | $0.00 | $0 | 22,100 | Direct |
| 15 Jun, 2026 | Shelley B Thunen | Director | Acquired A | 22,100 | $0.00 | $0 | 22,100 | Direct |
| 27 Mar, 2026 | Jeffrey P. George | Director | Acquired P | 5,592 | $8.92 | $49.89K | 5,592 | Direct |
| 27 Mar, 2026 | Daniel R. Chevallard | Chief Financial Officer | Acquired P | 7,500 | $8.57 | $64.28K | 12,886 | Direct |
| 27 Mar, 2026 | Evert B. Schimmelpennink | President, Ceo And Secretary | Acquired P | 28,089 | $8.95 | $251.41K | 77,289 | Direct |
| 02 Jan, 2026 | Shawn Olsson | Chief Commercial Officer | Acquired A | 84,200 | $0.00 | $0 | 84,200 | Direct |
| 02 Jan, 2026 | Daniel R. Chevallard | Chief Financial Officer | Acquired A | 84,200 | $0.00 | $0 | 84,200 | Direct |
| 02 Jan, 2026 | Marc Odrich | Chief Medical Officer | Acquired A | 84,200 | $0.00 | $0 | 84,200 | Direct |
| 02 Jan, 2026 | Evert B. Schimmelpennink | President, Ceo And Secretary | Acquired A | 358,100 | $0.00 | $0 | 358,100 | Direct |
| 02 Jan, 2026 | Marc Odrich | Chief Medical Officer | Acquired A | 14,000 | $0.00 | $0 | 14,000 | Direct |
| 02 Jan, 2026 | Shawn Olsson | Chief Commercial Officer | Acquired A | 14,000 | $0.00 | $0 | 14,000 | Direct |
| 02 Jan, 2026 | Daniel R. Chevallard | Chief Financial Officer | Acquired A | 14,000 | $0.00 | $0 | 14,000 | Direct |
| 17 Nov, 2025 | Shawn Olsson | Chief Commercial Officer | Acquired M | 10,000 | $2.08 | $20.80K | 14,733 | Direct |
| 17 Nov, 2025 | Shawn Olsson | Chief Commercial Officer | Disposed S | 4,212 | $25.74 | $108.41K | 10,521 | Direct |
| 17 Nov, 2025 | Shawn Olsson | Chief Commercial Officer | Disposed S | 5,788 | $26.37 | $152.61K | 4,733 | Direct |